Mara Goldstein
Stock Analyst at Mizuho
(2.47)
# 2,397
Out of 5,146 analysts
70
Total ratings
46.15%
Success rate
13.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintains: Outperform | $410 → $600 | $20.75 | +2,791.57% | 2 | Jan 27, 2026 | |
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $8.56 | +250.47% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $3.83 | +161.10% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $5.83 | +37.22% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $20.27 | +107.20% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $11.98 | +317.36% | 2 | Jan 22, 2024 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $99.98 | -22.98% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $13.46 | -47.99% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.48 | +440.54% | 5 | Nov 20, 2023 | |
| NKTR Nektar Therapeutics | Reiterates: Neutral | $90 | $70.37 | +27.90% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $18.20 | -80.77% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.66 | +21,586.75% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $5.24 | +281.68% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $122.46 | +6.16% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $5.78 | -65.40% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.76 | +581.82% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $62.89 | -68.20% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $11.00 | +336.36% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $30.82 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $6.56 | +113.41% | 1 | Oct 12, 2017 |
Syndax Pharmaceuticals
Jan 27, 2026
Maintains: Outperform
Price Target: $410 → $600
Current: $20.75
Upside: +2,791.57%
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $8.56
Upside: +250.47%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $3.83
Upside: +161.10%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $5.83
Upside: +37.22%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $20.27
Upside: +107.20%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $11.98
Upside: +317.36%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $99.98
Upside: -22.98%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $13.46
Upside: -47.99%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.48
Upside: +440.54%
Nektar Therapeutics
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $70.37
Upside: +27.90%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $18.20
Upside: -80.77%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $1.66
Upside: +21,586.75%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $5.24
Upside: +281.68%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $122.46
Upside: +6.16%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $5.78
Upside: -65.40%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.76
Upside: +581.82%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $62.89
Upside: -68.20%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $11.00
Upside: +336.36%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $30.82
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $6.56
Upside: +113.41%